Helping patients reclaim a life of possibility
March is Multiple Myeloma Awareness Month. This incurable disease affects increasingly young adult generation. In Europe, more than 50.900 people were diagnosed with myeloma in 2020[1]. Patient organisations from Central and Eastern Europe (CEE) have joined forces to create the documentary My myeloma: ready for the steps ahead, which premiered on 21th of March…
THE IMI T2EVOLVE Project and the Horizon 2020 QUALITOP Project have launched a European patient survey on CAR-T treatment. The survey aims to inform on patient and carer experiences and challenges of receiving CAR-T and to identify information needs and gaps across Europe. The results of the survey will be used for research purposes and…
Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel. “Health Basket” Each year, the Israel Ministry of Health nominates a Health…
Influenza (i.e. “flu”) and pneumococcal vaccinations positively impact the outcomes of myeloma patients. This is the central conclusion in the article Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma (MM) Patients: Influenza and Pneumococcal Vaccination in MM, published in Clinical Lymphoma, Myeloma and Leukaemia. The article outlines an analysis of data…
Myeloma Patients Europe (MPE) is attending the 64th American Society of Hematology (ASH) Annual Meeting, the biggest haematology congress, held from 9 to 13 December in New Orleans (United States). MPE has interviewed haematology experts to summarise the latest updates on myeloma and AL amyloidosis:
The European Commission has approved marketing authorisation (e.g. a license) for melphalan flufenamide (also called melflufen), a drug marketed in Europe by Oncopeptides with the name of Pepaxti®. This follows the previous positive recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).
The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment. Teclistamab, alternatively known…
Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here. Alternatively known under the branded name “Revlimid”, lenalidomide is a drug licensed and commonly used in the treatment of myeloma – in newly diagnosed, maintenance and relapsed settings. Lenalidomide…